ScholarIQanswers from OpenAlex & ORCID
Philip R. Clingan
ResearcherPublications, citations & collaboration network
Philip R. Clingan is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Philip R. Clingan have?
ScholarIQindexed works
Philip R. Clingan has 70 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Philip R. Clingan have?
ScholarIQcitation count
Philip R. Clingan has 16,753 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Philip R. Clingan?
ScholarIQh-index
Philip R. Clingan has an h-index of 23 in OpenAlex.
What is the i10-index of Philip R. Clingan?
ScholarIQi10-index
Philip R. Clingan has an i10-index of 32 in OpenAlex.
What is the OpenAlex record for Philip R. Clingan?
ScholarIQopenalex
The OpenAlex for Philip R. Clingan is on the source record.
What are the most-cited papers on Philip R. Clingan?
ScholarIQmost cited works
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Dómine, Philip R. Clingan, Maximilian J. Hochmair, Steven Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Belén Rubio‐Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E. Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M. Catherine Pietanza, Marina Chiara Garassino
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J. Hochmair, Philip R. Clingan, Steven Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Edward B. Garon, Silvia Novello, Belén Rubio‐Viqueira, Michael Boyer, Takayasu Kurata, Jhanelle E. Gray, Jing Yang, Tuba Öcek Baş, M. Catherine Pietanza, Marina Chiara Garassino
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah